| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2016-12-04 | Celgene (USA - NJ) Dana-Farber Cancer Institute (USA - MA) University of Arkansas for Medical Sciences (USA - Ar) | Myeloma Genome Project | myeloma | collaboration |
Cancer - Oncology | Collaboration agreement |
| 2016-12-03 | Novartis (Switzerland) Selexys Pharmaceuticals (USA - OK) | crizanlizumab (anti-P-selectin antibody SelG1) | sickle cell disease | product acquisition | Genetic diseases - Blood diseases | Product acquisition |
| 2016-12-02 | CytRx Corporation (USA - CA) | nomination |
Cancer - Oncology | Nomination | ||
| 2016-12-02 | Acetylon Pharmaceuticals (USA - MA) Regenacy Pharmaceuticals (USA - MA) | diabetic neuropathy, sickle cell disease, beta-thalassemia | CNS diseases - Rare diseases - Genetic diseases - Hematological diseases | Establishment of a new subsidiary in the US | ||
| 2016-12-01 | Kite Pharma (USA - CA) | nomination |
Cancer - Oncology - Rare diseases | Nomination | ||
| 2016-12-01 | TESLA (Tumor neoantigEn SeLection Alliance) | advanced melanoma, colorectal cancer, non-small cell lung cancer | R&D |
Cancer - Oncology | R&D agreement | |
| 2016-12-01 | Aimmune Therapeutics (USA - CA) previously Allergen Research Corporation (ARC) | nomination | Allergic diseases | Nomination | ||
| 2016-11-30 | Genticel (France) Serum Institute of India (India) | Vaxiclase platform | pertussis | licensing |
Infectious diseases | Milestone |
| 2016-11-30 | Ablynx (Belgium) Novo Nordisk (Denmark) | multi-specific Nanobody® drug candidates | undisclosed | research - R&D | undisclosed | Milestone |
| 2016-11-30 | Takeda Pharmaceutical (Japan) | dengue fever | construction of a production plant |
Infectious diseases | Construction of a production plant | |
| 2016-11-30 | Bioverativ (USA - MA) Sangamo Biosciences (USA - MA) | zinc finger nuclease (ZFN)-mediated genome editing program | hemoglobinopathies | licensing |
Rare diseases - Genetic diseases - Hematological diseases | Licensing agreement |
| 2016-11-29 | Audentes Therapeutics (USA - CA) | Rare diseases - Genetic diseases | Opening of new premises | |||
| 2016-11-29 | AMRI (USA - NY) Shire (UK - USA) | undisclosed product | production manufacturing |
undisclosed | Production agreement | |
| 2016-11-29 | Arrowhead Pharmaceuticals (USA - CA) | restructuring |
R&D agreement | |||
| 2016-11-29 | Accinov (France) Biodextris (Canada) | services for the development, production and testing of bio/pharmaceutical products | collaboration co-marketing |
Technology - Services | Collaboration agreement | |
| 2016-11-29 | RegenXBio (USA - MD) Voyager Therapeutics (USA - MA) | three specific NAV vector sequences covered by NAV Technology Platform | neurological diseases | licensing | Neurological diseases | Licensing agreement |
| 2016-11-29 | Audentes Therapeutics (USA - CA) | opening of new premises | Rare diseases - Genetic diseases | Opening of new premises | ||
| 2016-11-28 | OSE Immunotherapeutics (France) | nomination |
Cancer - Oncology - Autoimmune diseases | Nomination | ||
| 2016-11-28 | Boehringer Ingelheim (Germany) China Southeast University (China) | drug targeting hair cell regeneration | hearing loss | R&D |
Otorhinolaryngology - Regenerative medicine | R&D agreement |
| 2016-11-28 | Addex Therapeutics (Switzerland) | nomination |
Nomination |
